Efficacy and safety of lopinavir/ritonavir-based antiretroviral therapy in HIV-1-infected subjects with advanced disease: a systematic review and meta-analysis

Abstract

ABSTRACT  Aim: We examined the literature for the efficacy, safety and tolerability of lopinavir/ritonavir (LPV/r)-based regimens in antiretroviral therapy naive HIV-1-infected subjects with advanced disease. Materials & methods: Virologic and immunologic efficacy and adverse event results from prospective, randomized controlled trials evaluating LPV/r + two nucleoside reverse transcriptase inhibitors were examined using random-effects meta-analyses. Emergence of resistance was determined using data extracted from published material. Results: Thirteen studies (including ten 96-week studies) met search criteria. Virologic responses were similar at 96 weeks between subjects with HIV-1 infection treated with LPV/r-based antiretroviral therapy when stratified by baseline HIV-1 RNA or CD4+ T-cell count; immunologic responses were similar when stratified by CD4+ T-cell count. Conclusion: Through 96 weeks of treatment, the efficacy, safety and tolerability of LPV/r-based regimens were comparable in subjects with and without advanced HIV-1 disease.